Squalamine News and Research

RSS

Targeting the formation of alpha-synuclein aggregates may slow Parkinson's progression

Aggregates of the protein alpha-synuclein arising in the gut may play a key role in the development of Parkinson's disease.

13 Nov 2019

Combining toxic herbicide with sugar-binding proteins may trigger Parkinsonism

Combining low doses of a toxic herbicide with sugar-binding proteins called lectins may trigger Parkinsonism -- symptoms typical of Parkinson's disease like body tremors and slowing of body motions -- after the toxin travels from the stomach to the brain.

4 Dec 2018

Study finds link between upper GI infections and protein implicated in Parkinson’s disease

Acute and chronic infections in a person's upper gastrointestinal tract appear to be linked to Parkinson's disease, say scientists at Georgetown University Medical Center and their collaborators at the National Institutes of Health and other institutions.

28 Jun 2017

Synthesized steroid prevents lethal protein buildup in animal model of Parkinson's disease

A synthesized steroid mirroring one naturally made by the dogfish shark prevents the buildup of a lethal protein implicated in some neurodegenerative diseases, reports an international research team studying an animal model of Parkinson's disease.

17 Jan 2017

Naturally-occurring compound can inhibit early formation of toxins linked to Parkinson's Disease

A naturally-occurring compound has been found to block a molecular process thought to underlie Parkinson's Disease, and to suppress its toxic products, scientists have reported.

17 Jan 2017

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

6 Mar 2014

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical, Inc., a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

10 Jul 2013

Ohr Pharmaceutical declares 1-for-3 reverse split of its outstanding common stock

Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.

3 Jun 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

Antivirals from shark cartilage compound squalamine

A unique compound originally isolated from sharks could prove to be a promising treatment for hepatitis B and C and other viral diseases, researchers say. Known as squalamine, the drug has not yet been tested as an antiviral agent in humans, but it has been given to hundreds of people enrolled in clinical trials designed to test its usefulness for other conditions. Researchers say they hope to begin human trials to test the compound’s antiviral activity within the next year.

21 Sep 2011

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004